PDF(Pubmed)
Abstract：
UNASSIGNED: This preliminary retrospective cohort study investigates the potential additive prophylactic effect of erenumab, a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor, in combination with ongoing onabotulinumtoxin A (onaBoNT-A) treatment in patients suffering from chronic migraine.
UNASSIGNED: The study included 218 patients and investigated the effects of adding erenumab to the existing treatment regimen. The primary outcome was the MIDAS (Migraine Disability Assessment) score assessed 3 months after the introduction of erenumab.
UNASSIGNED: The results indicated a significant improvement of the MIDAS score, suggesting a reduction in migraine-related disability following the addition of erenumab to onaBoNT-A. In the inter group comparison, dual therapy showed a significantly greater reduction of the MIDAS when compared to a switch from onaBoNT-A to erenumab monotherapy, but not compared to initiation of onaBoNT-A monotherapy. It is hypothesized that the observed additive effects are due to the independent modes of action of erenumab and onabotulinumtoxin A.
UNASSIGNED: This study suggests that the combination of erenumab with onaBoNT-A may offer an improved approach for the treatment of chronic migraine in selected patients. However, the results highlight the need for prospective, controlled studies to validate these findings and determine the optimal combination of treatments tailored to the individual patient.
UNASSIGNED: The study included 218 patients and investigated the effects of adding erenumab to the existing treatment regimen. The primary outcome was the MIDAS (Migraine Disability Assessment) score assessed 3 months after the introduction of erenumab.
UNASSIGNED: The results indicated a significant improvement of the MIDAS score, suggesting a reduction in migraine-related disability following the addition of erenumab to onaBoNT-A. In the inter group comparison, dual therapy showed a significantly greater reduction of the MIDAS when compared to a switch from onaBoNT-A to erenumab monotherapy, but not compared to initiation of onaBoNT-A monotherapy. It is hypothesized that the observed additive effects are due to the independent modes of action of erenumab and onabotulinumtoxin A.
UNASSIGNED: This study suggests that the combination of erenumab with onaBoNT-A may offer an improved approach for the treatment of chronic migraine in selected patients. However, the results highlight the need for prospective, controlled studies to validate these findings and determine the optimal combination of treatments tailored to the individual patient.
摘要：
■这项初步回顾性队列研究调查了erenumab的潜在累加预防作用，一种完全的人单克隆抗体，可阻断降钙素基因相关肽受体，与慢性偏头痛患者正在进行的抑瘤毒素A（onaBoNT-A）治疗相结合。
■该研究包括218名患者，并调查了在现有治疗方案中添加erenumab的效果。主要结果是在引入erenumab后3个月评估的MIDAS（偏头痛残疾评估）评分。
■结果表明，MIDAS评分显着提高，表明在onaBoNT-A中添加erenumab后偏头痛相关的残疾减少。在组间比较中，与从onaBoNT-A转换为erenumab单药治疗相比，双重治疗显示MIDAS的减少明显更大，但与开始onaBoNT-A单药治疗相比。据推测，观察到的累加效应是由于erenumab和onabotulinumtoxinA的独立作用方式所致。
■该研究表明，erenumab与onaBoNT-A的组合可能为治疗选定患者的慢性偏头痛提供了一种改进的方法。然而,结果强调了前瞻性的必要性，对照研究，以验证这些发现，并确定针对个体患者量身定制的最佳治疗组合。
■该研究包括218名患者，并调查了在现有治疗方案中添加erenumab的效果。主要结果是在引入erenumab后3个月评估的MIDAS（偏头痛残疾评估）评分。
■结果表明，MIDAS评分显着提高，表明在onaBoNT-A中添加erenumab后偏头痛相关的残疾减少。在组间比较中，与从onaBoNT-A转换为erenumab单药治疗相比，双重治疗显示MIDAS的减少明显更大，但与开始onaBoNT-A单药治疗相比。据推测，观察到的累加效应是由于erenumab和onabotulinumtoxinA的独立作用方式所致。
■该研究表明，erenumab与onaBoNT-A的组合可能为治疗选定患者的慢性偏头痛提供了一种改进的方法。然而,结果强调了前瞻性的必要性，对照研究，以验证这些发现，并确定针对个体患者量身定制的最佳治疗组合。
